Analysis Of Noggin Function Using Monoclonal Antibodies

(will follow)

This is the 3rd volume in a series of reviews centered on the single major topic of bone replacement, discussing the biology of stem cells and cell signals, the knowledge needed to make stem cell-engineered bone tissue a reality, and how to prevent bone allograft infection. Useful as a followup to its predecessors, and as a stand-alone reference, it will interest a broad audience from orthopedists and bioengineers to dentists.

This Series provides a comprehensive survey of the major topics in the field of developmental biology. The volumes are valuable to researchers in animal and plant development, as well as to students and professionals who want an introduction to cellular and molecular mechanisms of development. The Series has recently passed its 30-year mark, making it the longest-running forum for contemporary issues in developmental biology.

Inflammatory bowel diseases (IBD), are chronic and progressive diseases. Long-term complications are demolition surgery and colon-rectal cancer (CRC). A treat-to-target approach aims to modify the natural course of these diseases. Targets are pre-defined therapeutic goals demonstrated to prevent end-organ disfunction and disability in the long-term period. According to the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) indications, mucosal healing (MH) and clinical remission are the main targets in IBDs. Recently, the concept of remission and evidence on new targets included histological remission and transmural healing as future new targets. It remains controversial whether achieving these targets is associated with significantly better long-term disease outcomes. In this Research Topic, we aim to systematically review current evidence and future perspectives on therapeutic targets in IBD including mucosal and transmural healing.